

#10
Dale
12/11/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: JENSEN, M.
Serial No.: 09/846,637
Filed: April 30, 2001
Conf. No.: 4845
For: *SELECTION SYSTEMS FOR
GENETICALLY MODIFIED CELLS*
Art Unit: 1632
Examiner: Chen, Liping

02 DEC - 6 PM 1:30
RECEIVED
TECH CENTER 1600/2900

RECEIVED

TRANSMITTAL LETTER

DEC 10 2002

Commissioner for Patents
~~U.S. Patent and Trademark Office~~
P.O. Box 2327
Arlington, VA 22202

TECH CENTER 1600/2900

Sir:

Transmitted herewith via hand delivery is a Supplemental Information Disclosure Statement, PTO-Form 1449 (3 pages), and cited references for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

- The Commissioner is hereby authorized to charge any fee, including any submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By: 
Stephanie Seidman
Registration No. 33,779

Date: December 5, 2002

Attorney Docket No.: 24751-2502

Address all correspondence to:

Stephanie Seidman, Esq.

HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

RECEIVED
DEC 10 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: *JENSEN, M.*
Serial No.: 09/846,637
Filed: April 30, 2001
Confirmation No.: 4845
For: *SELECTION SYSTEMS FOR
GENETICALLY MODIFIED CELLS*
Art Unit: 1632
Examiner: Chen, Liping

RECEIVED
TECH CENTER 1600/2900
02 DEC -6 PM 1:30

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Since this Supplemental Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. The Forms PTO-1449 (3 pages) and cited references are provided herewith in connection with the above-captioned application.

U.S.S.N. 09/846,637

JENSEN, M.

Supplemental Information Disclosure Statement

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant respectfully requests that the Examiner review the foregoing reference and information and that they be made of record in the file history of the above-captioned application.

* * *

Respectfully submitted,
HELLER EHRLICH WHITE & McAULIFFE LLP

By:

✓Stephanie L. Seidman
Registration No. 33,779

Date: December 5, 2002

Attorney Docket No. 24751-2502

Address all correspondence to:

Stephanie L. Seidman, Esq.

Heller Ehrlich White & McAuliffe LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246

Telephone: (858)450-8400

Facsimile: (858)587-5360

EMAIL sseidman@HEWM.com

RECEIVED

DEC 10 2002

02 Sheet 1 of 3

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.

SERIAL NO.

10751-2502

09/846,637

TECH CENTER 1600/2900

02 DEC - 6 PM
RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
16/01/2000LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
Jensen, Michael C.FILING DATE
April 30, 2001GROUP
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	5	1	6	6	0	5	9	11/24/92	Pastan <i>et al.</i>	435	69.7	05/03/91
	B	5	6	6	5	5	8	3	09/09/97	Collart <i>et al.</i>	435	191	08/12/88
	C	5	8	5	1	8	1	9	12/22/98	Gottesman <i>et al.</i>	435	320.1	05/31/95
	D	5	9	7	6	8	4	8	11/02/99	Davis <i>et al.</i>	435	183	01/30/92
	E	6	1	4	7	1	9	4	11/14/00	Collart <i>et al.</i>	530	387.1	09/08/97

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No
	F	9	1	0	0	3	6	1	01/10/91	PCT	C12P 21	06	
	G	9	8	3	0	7	0	9	07/16/98	PCT	C12N 15	86	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	H	Beckerman <i>et al.</i> "Single-Copy <i>IMH3</i> Allele is Sufficient to Confer Resistance to Mycophenolic Acid in <i>Candida albicans</i> and To Mediate Transformation of Clinical <i>Candida</i> Species," <i>Infection and Immunity</i> 69(1): 108-114 (2001)
	I	Collart, F.R. and E. Huberman, "Amplification of the IMP Dehydrogenase Gene in Chinese Hamster Cells Resistant to Mycophenolic Acid," <i>Molecular and Cellular Biology</i> 7(9): 3328-3331 (1987)
	J	Collart and Huberman, "Cloning and Sequence Analysis of the Human and Chinese Hamster Inosine-5'-monophosphate Dehydrogenase cDNAs", <i>J. Biol. Chem.</i> , 263(30):15769-15772 (1988)
	K	Davis <i>et al.</i> , "Histidine to alanine Mutants of Human Dihydroorotate Dehydrogenase", <i>Biochem. Pharmacol.</i> , 54:459-565 (1997)
✓	L	Digits, J.A. and L. Hedstrom, "Drug Selectivity Is Determined by Coupling Across the NAD ⁺ Site of IMP Dehydrogenase," <i>Biochemistry</i> 39: 1771-1777 (2000)
✓	M	Digits <i>et al.</i> , "Species-Specific Inhibition of Inosine 5'-Monophosphate Dehydrogenase by Mycophenolic Acid", <i>Biochem.</i> , 38:15388-15397 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		RECEIVED APR 10 2002 TECH CENTER 1600/2900	
		FILING DATE April 30, 2001	GROUP 1632

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

N	Drews <i>et al.</i> , "Passage to Nonselective Media Transiently alters Growth of Mycophenolic Acid-Resistant Mammalian Cells expressing the <i>Escherichia coli</i> Xanthine-Guanine Phosphoribosyltransferase Gene: Implications for Sequential Selection Strategies," <i>Analytical Biochemistry</i> <u>235</u> : 215-226 (1996)
O	Farazi <i>et al.</i> , "Isolation and Characterization of Mycophenolic Acid-resistant Mutants of Inosine-5'-monophosphate Dehydrogenase", <i>J. Biol. Chem.</i> , <u>272</u> (2):961-965 (1997)
P	Glesne <i>et al.</i> , "Chromosomal Localization and Structure of the Human Type II IMP Dehydrogenase Gene (IMPDH2)", <i>Genomics</i> , <u>16</u> :274-277 (1993)
Q	Goshorn <i>et al.</i> , "Genetic Analysis of Prototrophic Natural Variants of <i>Candida albicans</i> ," <i>Genetics</i> <u>123</u> : 667-673 (1989)
R	Gustafson <i>et al.</i> , "Identification of a new antifungal target site through a dual biochemical and molecular-genetics approach," <i>Curr Genet</i> <u>30</u> : 159-165 (1996)
S	Gustafson <i>et al.</i> , "Isolation, Characterization, and Genetic Analysis of <i>Aspergillus nidulans</i> Mutants Resistant to the Antifungal Compound LY214352," <i>Current Microbiology</i> <u>23</u> : 39-44 (1991)
T	Hatse <i>et al.</i> , "Role of Antimetabolites of Purine and Pyrimidine Nucleotide Metabolism in Tumor Cell Differentiation", <i>Biochem. Pharmacol.</i> , <u>58</u> :539-555 (1999)
U	Hege and Roberts, "T-cell gene therapy", <i>Curr. Opin. Biotechnol.</i> , <u>7</u> :629-634 (1996)
V	Hodges <i>et al.</i> , "Increased Activity, Amount, and Altered Kinetic Properties of IMP Dehydrogenase from Mycophenolic Acid-resistant Neuroblastoma", <i>J. Biol. Chem.</i> , <u>264</u> (30):18137-18141 (1989)
W	Huberman <i>et al.</i> , "Mutagen-induced resistance to mycophenolic acid in hamster cells can be associated with increased inosine 5'-phosphate dehydrogenase activity," <i>Proc. Natl. Acad. Sci. USA</i> <u>78</u> (5): 3151-3154 (1981)
X	James <i>et al.</i> , "Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated by counterflow elutriation," <i>Bone Marrow Transplantation</i> <u>24</u> : 815-21 (1999)
Y	James <i>et al.</i> , "Mild preconditioning at low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug resistant dihydrofolate reductase activity," <i>Blood</i> <u>96</u> (4): 1334-1341 (2000)
Z	Kiguchi <i>et al.</i> , "Cell Differentiation and Altered IMP Dehydrogenase Expression Induced in Human T-Lymphoblastoid Leukemia Cells by Mycophenolic Acid and Tiazofurin," <i>Experimental Cell Research</i> <u>187</u> : 47-53 (1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		ATTY. DOCKET NO. 24751-2502	SERIAL NO. 09/846,637
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT Jensen, Michael C.	<i>RECEIVED</i> DEC 10 2002
		FILING DATE April 30, 2001	GROUP 1632 TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Kohler <i>et al.</i> , "Overexpression of a Cloned IMP Dehydrogenase Gene of <i>Candida albicans</i> Confers Resistance to the Specific Inhibitor Mycophenolic Acid," <i>Journal of Bacteriology</i> <u>179</u> (7): 2331-2338 (1997)
	AB	Licht <i>et al.</i> , "In Vivo Drug-Selectable Genes: A New Concept in Gene Therapy", <i>Stem Cells</i> , <u>15</u> :104-111 (1997)
	AC	Lightfoot <i>et al.</i> , "Gene amplification and dual point mutations of mouse IMP dehydrogenase associated with cellular resistance to mycophenolic acid", <i>Biochim. Biophys. Acta</i> <u>1217</u> :156-162 (1994)
	AD	May <i>et al.</i> , "Protection of Mice From Lethal Doses of Methotrexate by Transplantation with Transgenic Marrow Expressing Drug-Resistant Dihydrofolate," <i>Blood</i> <u>86</u> (6): 2439-2448 (1995)
	AE	Minet <i>et al.</i> , "Cloning and sequencing of a human cDNA coding for dihydroorotate dehydrogenase by complementation of the corresponding yeast mutant," <i>Gene</i> <u>121</u> : 393-6 (1992)
	AF	Natsumeda and Carr, "Human Type I and II IMP Dehydrogenases as Drug Targets", <i>Ann. N.Y. Acad. Sci.</i> , <u>696</u> :88-93 (1993)
	AG	Natsumeda <i>et al.</i> , "Two Distinct cDNAs for Human IMP Dehydrogenase," <i>The Journal of Biological Chemistry</i> <u>265</u> (9): 5292-5295 (1990)
	AH	Sintchak and Nimmesgern, "The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors", <i>Immunopharmacol.</i> , <u>47</u> :163-184 (2000)
	AI	Snyder <i>et al.</i> , "Molecular Characterization of IMP Dehydrogenase in Acquired Resistance to Mycophenolic Acid," <i>Purine and Pyrimidine in Man VIII</i> Sahota, A. and M. Taylor (Eds.) New York: Plenum Press pgs. 725-728 (1995)
	AJ	Spencer <i>et al.</i> , "A Gene Transfer Strategy for Making Bone Marrow Cells Resistant to Trimetrexate", <i>Blood</i> , <u>87</u> (6):2579-2587 (1996)
	AK	Staib <i>et al.</i> , "A molecular genetic system for the pathogenic yeast <i>Candida dubliniensis</i> ," <i>Gene</i> <u>242</u> : 393-8 (2000)
	AL	Sugimoto <i>et al.</i> , " <i>In vivo</i> drug-selectable markers in gene therapy," <i>Leukemia</i> <u>11</u> (Suppl)3: 552-6 (1997)
	AM	Ullman, B., "Characterization of Mutant Murine Lymphoma Cells with Altered Inosinate Dehydrogenase Activities," <i>The Journal of Biological Chemistry</i> <u>258</u> (1): 523-8 (1983)
	AN	Zimmermann <i>et al.</i> , "Characterization of the Human Inosine-5'-monophosphate Dehydrogenase Type II Gene", <i>J. Biol. Chem.</i> , <u>270</u> (12):6808-6814 (1994)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	